4 results about "Salmonella escanaba" patented technology

The present invention discloses a pharmaceutical composition, its manufacturing method, and its use, wherein the pharmaceutical composition comprises a first active ingredient, a second active ingredient, and a pharmaceutically acceptable carrier or excipient, the first active ingredient being a microbial agent containing one or more of Staphylococcus aureus, Bordetella pertussis, diphtheria toxoid, tetanus toxoid, Salmonella typhi, or Salmonella paratyphi, and the second active ingredient comprising polyinosinic acid, polycytidylic acid, and vitamins. The pharmaceutical composition is an artificial active immunotherapy for tumors, which, by "stimulating" the entire immune system, activates the human immune system using bacteria to kill cancer cells, making the treatment extremely stable and reliable, significantly saving and extending the lives of cancer patients, while simultaneously being extremely safe, having very few toxic side effects, and having low manufacturing costs.

This invention discloses the application of *Lactobacillus johnsonii* cell-free supernatant in inhibiting *Salmonella* biofilms, belonging to the field of microbial technology. This invention provides a novel use for *Lactobacillus johnsonii* BNCC186110 cell-free supernatant, which can inhibit the formation of *Salmonella typhimurium* SL1344 and 14028 biofilms, disrupt *Salmonella typhimurium* SL1344 and 14028 biofilms, thereby reducing the colonization of *Salmonella typhimurium* SL1344 and 14028.

This invention belongs to the field of microbiology, specifically relating to the application of albizophenolic compounds. These compounds inhibit pathogenic bacteria such as Salmonella, Mycobacterium smegmatis, Enterococcus faecalis, and Staphylococcus aureus, and inhibit the growth of human lung cancer cells and human breast cancer cells, exhibiting bactericidal and anticancer activities. They are suitable for developing products for everyday household use, medical care, and animal husbandry, with broad prospects for industrial application.

This invention discloses *Amycolatopsis* sp., its culture, metabolites, bacterial agents, and applications. The *Amycolatopsis* sp. provided by this invention has strain number TRM77291 and accession number CCTCC M 2024327 at the China Center for Type Culture Collection. This strain exhibits antibacterial activity against Erwinia, Salmonella, *Escherichia coli*, and *Pseudomonas aeruginosa*. This invention is of significant importance for the control of Gram-negative bacterial infections and the research of novel actinomycete-derived drugs.